ACTA1 and pulmonary fibrosis: Wei et al.[13] have reported that miR‐133 delivery was able to decrease α‐SMA expression and Collagen I deposition in lung fibroblasts, thus reducing cell transition into myofibroblast and pulmonary fibrosis alone or following TGF‐β treatment.